Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...

Donald Patrick McDonnell, Ph.D., has been awarded the Endocrine Society’s John D. Baxter Prize for Entrepreneurship for discovering hormone therapies for treating breast and prostate cancer, the ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Kairos Pharma (NYSE American: KAPA) has added Huntsman Cancer Institute in Salt Lake City as a site for its Phase 2 clinical trial of ENV105 for cas ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

The FDA has granted a 510 (k) clearance to the Ibex Prostate Detect software (formerly Galen Second Read). The Ibex Prostate ...

Kairos Pharma Ltd. , a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of Huntsman Cancer ...